FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

George Blackledge

Research Profile

Disorders

Chemicals & Drugs

Activities & Behaviors

Drug Evaluation

Procedures

Antineoplastic Combined Chemotherapy Protocols

Concepts & Ideas

Co-author Network

Publications

TOP 3
Peter R Carroll; David A Benaron; George Blackledge; Fergus V Coakley; Anthony V D'amico; Celestia S Higano; Peter Iversen; Michael W Kattan; David M Nanus; Joel B Nelson; William K Oh; Mack Roach; William R Sellers; Matthew R Smith; Mary Carole McMann; Philip W Kantoff
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.
Peter Iversen; Chris J Tyrrell; Amir V Kaisary; JB Anderson; L Baert; Teuvo Tammela; M Chamberlain; Kevin Carroll; K Gotting-Smith; George Blackledge
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
Chris J Tyrrell; Amir V Kaisary; Peter Iversen; JB Anderson; L Baert; Teuvo Tammela; M Chamberlain; A Webster; George Blackledge
A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of George Blackledge (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2003: Peter R Carroll; David A Benaron; George Blackledge; Fergus V Coakley; Anthony V D'amico; Celestia S Higano; Peter Iversen; Michael W Kattan; David M Nanus; Joel B Nelson; William K Oh; Mack Roach; William R Sellers; Matthew R Smith; Mary Carole McMann; Philip W Kantoff
Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.
The Journal of urology 2003;170(6 Pt 2):S3-5.
1998: Peter Iversen; Chris J Tyrrell; Amir V Kaisary; JB Anderson; L Baert; Teuvo Tammela; M Chamberlain; Kevin Carroll; K Gotting-Smith; George Blackledge
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
Urology 1998;51(3):389-96.
1998: Chris J Tyrrell; Amir V Kaisary; Peter Iversen; JB Anderson; L Baert; Teuvo Tammela; M Chamberlain; A Webster; George Blackledge
A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.
European urology 1998;33(5):447-56.
1998: G J Kolvenbag; George Blackledge; K Gotting-Smith
Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.
The Prostate 1998;34(1):61-72.
1996: N S Stuart; J Warwick; George Blackledge; D Spooner; C Keen; A R Taylor; C Tyrell; D J Webster; Helena Earl
A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer.
European journal of cancer (Oxford, England : 1990) 1996;32A(11):1888-92.
1996: G J Kolvenbag; George Blackledge
Worldwide activity and safety of bicalutamide: a summary review.
Urology 1996;47(1A Suppl):70-9; discussion 80-4.
1995: O P Clinton; T J Priestman; T N Latief; Helena Earl; A Murphy; George Blackledge; J Dunn; P Baker
A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1995;7(4):251-6.
1995: C J Williams; V L Barley; George Blackledge; C G Rowland; Chris J Tyrrell; F Bachelot; A Dermaille; P Fargeot; M Namer; J Pouillart
Multicentre cross-over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1995;7(2):87-92.
1994: Michael H Cullen; N S Stuart; C Woodroffe; A Murphy; J Fletcher; George Blackledge; J Anthony Child; R J Grieve; E L Jones
ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):779-87.
1994: C W Redman; J Warwick; David M Luesley; R Varma; F G Lawton; George Blackledge
Intervention debulking surgery in advanced epithelial ovarian cancer.
British journal of obstetrics and gynaecology 1994;101(2):142-6.
1993: C J Williams; V L Barley; George Blackledge; C G Rowland; Chris J Tyrrell
Multicentre cross over study of aminoglutethimide and trilostane in advanced postmenopausal breast cancer.
British journal of cancer 1993;68(6):1210-5.
1993: C W Redman; J Mould; J Warwick; Terry P Rollason; David M Luesley; J Budden; F G Lawton; George Blackledge; K K Chan
The West Midlands epithelial ovarian cancer adjuvant therapy trial.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1993;5(1):1-5.
1992: B Waymont; T H Lynch; J A Dunn; L A Emtage; D G Arkell; D M Wallace; George Blackledge
Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer.
British journal of urology 1992;69(6):614-20.
1992: Edward S Newlands; George Blackledge; J A Slack; Gordon J S Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; Malcolm F G Stevens; MH Brampton
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
British journal of cancer 1992;65(2):287-91.
1992: C B Finn; David M Luesley; E J Buxton; George Blackledge; K Kelly; J A Dunn; S Wilson
Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review.
British journal of obstetrics and gynaecology 1992;99(1):54-8.
1991: M E O'Brien; BE Souberbielle; M E Cowan; C A Allen; David M Luesley; J J Mould; George Blackledge; GR Skinner
Glycoprotein patterns in normal and malignant cervical tissue.
Cancer letters 1991;58(3):247-54.
1991: L A Birchall; N P Bailey; George Blackledge
An overview of mitozantrone.
The British journal of clinical practice 1991;45(3):208-11.
1990: L A Emtage; J George; B J Boughton; C Trethowan; George Blackledge
Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/month.
European journal of cancer (Oxford, England : 1990) 1990;26(3):315-9.
1990: David J Kerr; J A Slack; P Secrett; Malcolm F G Stevens; George Blackledge; C Bradley; Stanley B Kaye
Relationship between the pharmacokinetics and toxicity of mitozolomide.
Cancer chemotherapy and pharmacology 1990;25(5):352-4.
1990: C W Redman; George Blackledge; K Kelly; J Powell; E J Buxton; David M Luesley
Early serum CA125 response and outcome in epithelial ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1990;26(5):593-6.
1990: E J Buxton; N Saunders; George Blackledge; K Kelly; C W Redman; J Monaghan; M E Paterson; David M Luesley
The potential for adjuvant therapy in early-stage cervical cancer.
Cancer chemotherapy and pharmacology 1990;26 Suppl():S17-21.
1989: M E O'Brien; Michael H Cullen; C Woodroffe; K Kelly; C Burman; K Palmer; N S Stuart; George Blackledge; J Sharpe
The role of metoclopramide in acute and delayed chemotherapy induced emesis: a randomised double blind trial.
British journal of cancer 1989;60(5):759-63.
1989: C B Finn; C W Redman; R Varma; David M Luesley; N S Stuart; George Blackledge
The role of postoperative alkylating agent therapy in early-stage epithelial ovarian cancer.
British journal of obstetrics and gynaecology 1989;96(8):1007-8.
1989: David M Luesley; K K Chan; F G Lawton; George Blackledge; J M Mould
Survival after negative second-look laparotomy.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1989;15(3):205-10.
1989: E J Buxton; N S Stuart; K A Kelly; George Blackledge
Changing character of cervical cancer in young women.
BMJ (Clinical research ed.) 1989;298(6676):829.
1989: N S Stuart; S M Crawford; George Blackledge; Edward S Newlands; J Slack; R Hoffman; Malcolm F G Stevens
A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES)--a new dihydrofolate reductase inhibitor.
Cancer chemotherapy and pharmacology 1989;23(5):308-10.
1988: C W Redman; S R Jones; David M Luesley; S E Nicholl; K Kelly; E J Buxton; K K Chan; George Blackledge
Peritoneal trauma releases CA125?
British journal of cancer 1988;58(4):502-4.
1988: C W Redman; M I Shafi; S Ambrose; F G Lawton; George Blackledge; David M Luesley; J W L Fielding; K K Chan
Survival following intestinal obstruction in ovarian cancer.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 1988;14(5):383-6.
1988: D B Smith; M J Lind; S B Kaye; Edward S Newlands; George Blackledge; A Gibson
A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).
British journal of cancer 1988;57(5):512-3.
1988: N S Stuart; George Blackledge; J Anthony Child; J Fletcher; T J Perren; C J O'Brien; E L Jones; Ian O Ellis; J A Kavanagh; K A Kelly
A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma--intensive two-phase chemotherapy.
Cancer chemotherapy and pharmacology 1988;22(2):141-6.
1988: N S Stuart; Michael H Cullen; T J Priestman; George Blackledge; Chris J Tyrrell
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
Cancer chemotherapy and pharmacology 1988;21(4):351-4.
1988: L A Emtage; C Trethowan; C Hilton; K Kelly; George Blackledge
Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
American journal of clinical oncology 1988;11 Suppl 2():S173-5.
1987: L A Emtage; P W Lewis; George Blackledge
The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
British journal of urology 1987;60(6):572-7.
1987: L A Emtage; T J Perren; N S Stuart; D G Arkell; D M Wallace; M A Hughes; J Cottam; D Farrar; C H Young; George Blackledge
Phase II study of Zoladex depot in advanced prostatic cancer with special reference to criteria of response and survival.
British journal of urology 1987;60(5):436-42.
1986: George Blackledge; T Latief; J J Mould; D Spooner; M Morrison
Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer: relationship of response to previous treatment.
European journal of cancer & clinical oncology 1986;22(9):1091-4.
1985: R N Clayton; L C Bailey; J Cottam; D Arkell; T J Perren; George Blackledge
A radioimmunoassay for GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu)6 AZA Gly10 GnRH.
Clinical endocrinology 1985;22(4):453-62.